NeoGenomics, Inc. (NASDAQ:NEO) Short Interest Update

NeoGenomics, Inc. (NASDAQ:NEO) was the target of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 10,021,133 shares, an increase of 23.9% from the January 15th total of 8,090,064 shares. Based on an average daily volume of 1,977,550 shares, the days-to-cover ratio is presently 5.1 days. Approximately 7.9% of the shares of the stock are short sold. Approximately 7.9% of the shares of the stock are short sold. Based on an average daily volume of 1,977,550 shares, the days-to-cover ratio is presently 5.1 days.

NeoGenomics Trading Up 1.9%

Shares of NASDAQ:NEO traded up $0.21 during trading on Monday, hitting $11.38. 2,620,739 shares of the company’s stock were exchanged, compared to its average volume of 1,536,580. The company has a current ratio of 3.91, a quick ratio of 3.62 and a debt-to-equity ratio of 0.41. The firm has a market cap of $1.47 billion, a P/E ratio of -12.93 and a beta of 1.58. The firm has a 50-day moving average price of $12.18 and a two-hundred day moving average price of $10.02. NeoGenomics has a 1-year low of $4.72 and a 1-year high of $14.73.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on NEO shares. Zacks Research raised NeoGenomics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 12th. Needham & Company LLC restated a “buy” rating and set a $14.00 target price on shares of NeoGenomics in a report on Monday, January 12th. Leerink Partners set a $14.00 price target on NeoGenomics in a report on Tuesday, October 28th. TD Cowen reiterated a “buy” rating on shares of NeoGenomics in a research report on Wednesday, January 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of NeoGenomics in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $12.00.

Insider Transactions at NeoGenomics

In other news, COO Warren Stone sold 22,128 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total transaction of $276,600.00. Following the completion of the sale, the chief operating officer owned 121,631 shares of the company’s stock, valued at approximately $1,520,387.50. This trade represents a 15.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Alicia C. Olivo sold 20,916 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total value of $250,992.00. Following the completion of the transaction, the executive vice president directly owned 31,083 shares in the company, valued at $372,996. The trade was a 40.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 2.40% of the company’s stock.

Institutional Trading of NeoGenomics

Several institutional investors and hedge funds have recently made changes to their positions in NEO. First Light Asset Management LLC lifted its stake in shares of NeoGenomics by 45.0% in the 3rd quarter. First Light Asset Management LLC now owns 9,927,269 shares of the medical research company’s stock valued at $76,639,000 after purchasing an additional 3,080,837 shares during the period. Greenhouse Funds LLLP grew its stake in shares of NeoGenomics by 10.6% during the third quarter. Greenhouse Funds LLLP now owns 8,220,657 shares of the medical research company’s stock worth $63,463,000 after purchasing an additional 789,510 shares during the period. American Century Companies Inc. increased its holdings in NeoGenomics by 6.0% in the second quarter. American Century Companies Inc. now owns 3,517,478 shares of the medical research company’s stock valued at $25,713,000 after purchasing an additional 197,876 shares during the last quarter. Geode Capital Management LLC lifted its stake in NeoGenomics by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 3,176,644 shares of the medical research company’s stock valued at $37,364,000 after buying an additional 44,733 shares during the period. Finally, Segall Bryant & Hamill LLC boosted its holdings in NeoGenomics by 0.5% during the second quarter. Segall Bryant & Hamill LLC now owns 2,362,049 shares of the medical research company’s stock worth $17,267,000 after buying an additional 11,303 shares during the last quarter. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.